AgingResearch.News

AgingResearch.News

Human trialCellular senescence

Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial

The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.

Why it mattersCellular senescence drives tissue inflammation and fibrosis during aging and chronic disease. This trial provides proof-of-principle evidence in humans that senolytic drugs can reduce senescent cell signatures and reverse organ-level fibrosis.

Cellular senescence drives tissue inflammation and fibrosis during aging and chronic disease. This trial provides proof-of-principle evidence in humans that senolytic drugs can reduce senescent cell signatures and reverse organ-level fibrosis.

Nature Metabolism · Koning M et al.

Top stories

Also new

See all

Today’s numbers

3 Oct
  1. 995Papers read
  2. 7About aging biology0.7% of papers read
  3. 4Stories57% of those

Stats

Plus

A feed ranked to your research.

From $3.95 a month.

See Plus